ClassNK, USMRC Join Forces

first_imgzoom The United States Maritime Resource Center (USMRC) in Middletown, Rhode Island and Japan’s classification society ClassNK, have inked a Memorandum of Understanding (MOU) on joint research and development activities for the maritime industry.The initial joint project will focus on the development of practical LNG bunkering simulation tools to further enhance USMRC’s existing niche portfolio of LNG bunkering training programs.This type of training, augmented with high fidelity simulations, better prepares mariners and shore-based personnel to safely handle LNG as a marine fuel. USMRC’s role will be to oversee the execution of the project.“Our goal is to support the safety of ships from not only from the technological point of view, but also the human factor perspective. The need for qualified seafarers who are familiar with the latest maritime technology is essential for the sustainable development of the shipping industry,” said ClassNK Executive Vice President Koichi Fujiwara. “USMRC not only has the specialized knowledge to address these issues, but also has rich experience in maritime training.” “We were the first to offer LNG bunkering safety training in the United States,” said USMRC President Brian Holden. “The signing of this MOU will allow us to take another leap forward in this area by developing practical, hands-on LNG bunkering simulation tools to make this training even better.”The MOU also calls for USMRC and ClassNK to work together to offer Dynamic Positioning and other critical training capabilities to meet the needs of the offshore energy sector.ClassNK also has agreed to support USMRC’s technical research and other activities related to maritime cybersecurity – an emerging and significant risk to maritime safety.last_img read more

Read More →

Canadian Black Government Leaders to Meet in Ontario

first_imgBlack legislative leaders, including Tony Ince, Minister of African Nova Scotia Affairs, are meeting in Ontario this week to discuss ways to build a better future for African Canadians. The second Black Government Leaders’ Summit will take place in Toronto from Aug. 10 to 13. The first summit took place in Nova Scotia in Birchtown, Shelburne Co. last year and brought together federal and provincial legislators. Mr. Ince co-chaired that meeting. “This summit is a chance for African Canadian leaders to discuss issues that affect our communities, from racism to jobs to leadership opportunities,” said Mr. Ince. “I am proud to be a black leader in Canada, and I look forward to meeting with fellow black leaders once more to talk about how we can continue to build a bright future for our children.” This year’s meeting will focus on several key areas: youth engagement, economic opportunities, education and health of African Canadians. “The Black Government Leaders’ Summit is a unique opportunity for federal, provincial and municipal leaders to work on policy issues that impact black Canadians, “said Michael Coteau, Minister of Children and Youth Services, and Minister Responsible for Anti-Racism. “Ontario is proud to host the second annual summit, building on the success of last year’s inaugural event. “I look forward to working with my counterparts to examine effective methods to enhance business innovation and advancement in the black community, develop black leadership, and improve health and education outcomes for black Canadians. As co-chair for this year’s summit, I am thrilled to meet with my colleagues at this significant occasion.” The meetings will feature presentations by international and local experts. The summit is in support of the goals of the United Nations’ International Decade for People of African Descent.last_img read more

Read More →

Merck spends 84 billion on Cubist to intensify defence against for superbug

Merck spends $8.4 billion on Cubist to intensify defence against for “superbug” threat FILE – In this Thursday, Feb. 28, 2013, file photo, Merck scientist Meizhen Feng conducts research to discover new HIV drugs in West Point, Pa. According to reports, Monday, Dec. 8, 2014, Merck will buy fellow drugmaker Cubist Pharmaceuticals for $8.4 billion, illustrating a new emphasis on combating so-called “superbugs” that have drawn dire warnings from global health organizations. (AP Photo/Matt Rourke, File) AddThis Sharing ButtonsShare to TwitterTwitterShare to FacebookFacebookShare to RedditRedditShare to 電子郵件Email by Tom Murphy, The Associated Press Posted Dec 8, 2014 5:26 am MDT Merck will spend $8.4 billion to buy Cubist Pharmaceuticals and push deeper into treating so-called “superbugs” that have drawn dire warnings from global health organizations.The company said Monday that the deal will give it stronger footing in hospital acute care and help it address antibiotic resistance, which the Whitehouse Station, New Jersey, drugmaker called a critical area of unmet medical need.Antibiotic-resistant infections are linked to 23,000 deaths and 2 million illnesses in the United States annually, according to the Centers for Disease Control and Prevention.The CDC has called the problem a threat to both health and economic stability, and President Obama in September ordered the government to create a national plan to fight them by early 2015.In April, the World Health Organization warned that without a co-ordinated effort, “the world is headed for a post-antibiotic era, in which common infections and minor injuries which have been treatable for decades can once again kill.”Antibiotics are used to kill or suppress the bacteria behind illnesses ranging from strep throat to urinary-tract infections. The drugs are considered one of the greatest advances in the history of medicine and have saved countless lives.But in recent decades some common bacteria have grown resistant to antibiotics that were once highly effective. Experts say overuse and misuse of the drugs by physicians has contributed to the rise of these so-called superbugs.Cubist draws most of its revenue from the antibiotic Cubicin, and it also has developed another treatment, Zerbaxa, that Merck said will help fight multi-drug resistant infections. The Food and Drug Administration is expected to make a decision on that drug later this month.Cubist paid more than $1 billion last year to buy two rival antibiotic developers: Trius Therapeutics and Optimer Pharmaceuticals Inc.Merck expects the acquisition to add more than $1 billion of revenue to its 2015 base and contribute significantly to its profit in 2016 and beyond.Merck will pay $102 per share of Cubist, a 37 per cent premium to its closing price on Friday.Shares of Cubist, based in Lexington, Massachusetts, soared nearly 36 per cent, or $26.52, to $100.88 Monday after markets opened, while Merck climbed slightly and broader trading indexes slipped.___AP Business Writer Michelle Chapman in New York contributed to this report. Murphy is based in Indianapolis. read more

Read More →